Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 10.12.2024

Fiskars Corporation   Stock Exchange Release 10.12.2024 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 10.12.2024   Date 10.12.2024  Exchange transaction Buy  Share class FSKRS  Amount  2,000  Average price/share 14.4600 EURHighest price/share 14.4600 EURLowest price/share 14.4600 EURTotal price 28,920.00 EUR        The shares held by Fiskars Corporation on 10.12.2024:   FSKRS  121,111       On

Zwipe AS – Subscription of new shares in the Company by exercise of subscription rights in the Rights Issue by primary insider

OSLO, NORWAY – 10 December 2024 - Reference is made to the stock exchange announcement published by Zwipe AS (the "Company") on 6 December 2024, regarding the commencement of the subscription period in a new issue of units (the "Units"), consisting of shares and warrants, with preferential rights for existing shareholders raising gross proceeds of approximately NOK 40 million (the "Rights Issue"). The shareholders of the Company on 3 December 2024 (and being registered as such in the Norwegian Central Securities Depository, Euronext Securities Oslo, as at the expiry of 5 December 2024 (

The Swedish Financial Supervisory Authority has approved TF Bank’s transfer of a majority stake in the subsidiary Rediem Capital AB

On 4 October 2024, TF Bank AB (publ) (”TF Bank” or the ”Bank”) announced that the Bank entered into a share purchase agreement (the “Share Purchase Agreement”) with Alektum Holding AB (publ) (”Alektum Holding”) and Erik Selin Fastigheter Aktiebolag (”Erik Selin Fastigheter”) regarding a transfer of a majority stake in the wholly owned subsidiary Rediem Capital AB (”Rediem”). Today, on 10 December 2024, the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) has approved Alektum Holding and Erik Selin Fastigheter as the new owners of Rediem. The Swedish Financial Supervisory

eSportRanker Highlights the Crypto Revolution in Esports Betting

Stockholm, Sweden - December 2024 – eSportRanker, a leading ranking and review platform for esports enthusiasts, has unveiled groundbreaking insights into the growing integration of cryptocurrency in eSports Betting. According to the latest research, the market is projected to grow significantly, reaching $12 billion by 2025. This evolution marks a major shift in how fans engage with competitive gaming and betting platforms, signaling a revolution in the industry.The report highlights a 150% increase in crypto-based esports betting transactions over the past year, with Bitcoin and Ethereum

#24-425 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

#24-424 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Telia Company announces results of tender offer in respect of certain outstanding GBP notes

Not for distribution, directly or indirectly, in or into or to any person located or resident in the United States, its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any state of the United States or the District of Columbia or to any U.S. Person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended) or in or into any other jurisdiction where it is unlawful to distribute this announcement. Telia Company AB (publ) (“Telia”) announces the results of the tender offer

STENOCARE 3.0 Strategy: Management Shares Insights in Exclusive Interview with Proinvestor.com

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Stenocare has announced its STENOCARE 3.0 strategy, unveiled on November 26, which marks a bold new chapter in its mission to become a leader in the medical cannabis industry. This transformative strategy positions Stenocare as a specialised Trading Company, focused on delivering high-quality, prescription-based medical cannabis products to carefully selected markets. By leveraging innovation and global partnerships, Stenocare aims to create superior value for patients and stakeholders.The management team recently

Eco Wave Power Announces Pricing of $3.0 Million Registered Direct Offering to Propel Commercial-Scale Wave Energy Deployment

Tel Aviv, Israel (December 10, 2024) – Eco Wave Power Global AB (publ) (Nasdaq: WAVE) (“Eco Wave Power” or the “Company”), a leading innovator in onshore wave energy technology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 300,000 American Depositary Shares (“ADSs”)(or ADS equivalents), each representing eight common shares of the Company, at a public offering price of $10.00 per ADS (or ADS equivalent) for gross proceeds of $3.0 million (the “Offering”), before deducting placement agent fees and offering expenses.

Hexagon Digital Wave partners with key players in the fire protection industry to accelerate the adoption of MAE technology - the most accurate method for testing SCBA cylinders

Centennial, CO, 10 December 2024:  Firefighters are dependent on safe air supplies to perform their job - Hexagon Digital Wave, a leading provider of innovative safety solutions, Denny’s Fire Control, a renowned supplier of fire protection equipment, and The Illinois Fire Service Institute (IFSI), the oldest continuous fire training institution in the United States, have joined forces to make Self-Contained Breathing Apparatus (SCBA) cylinder life extension technology more accessible to the fire service community. The most reliable and cost-efficient testing method SCBA cylinders used

Deep Dive into Great AI in iGaming: GR8 Tech’s AI Recommender

The buzz around artificial intelligence has reached a fever pitch, with industries scrambling to harness its potential. But amidst all the hype, the question remains: how is AI actually transforming the way we work, play, and interact?At iGaming News, we’re exploring this question with GR8 Tech in a three-part series on AI in the iGaming industry. To kick things off, we are taking a deep dive into GR8 Tech’s AI-powered Recommender, which is set to reshape iGaming platforms. What is an AI Recommender? Before we dive in, let’s clarify what GR8 Tech’s AI 

Correction: EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT. EQL Pharma AB (publ) (the “Company” or “EQL”) today announces that it has, through its wholly owned subsidiary EQL Pharma Int AB, signed a binding asset purchase agreement of DKK 120 million (corresponding to approximately SEK 185* million) (the “Asset Purchase Agreement”), to acquire a product portfolio. The product portfolio

First Delivery of Process Water from a Swedish Industry

Xoma has finalized an agreement with a company in the pulp and paper industry to deliver 1m³ of process water for an initial test.This will be delivered to Xoma at the end of January. Xoma will conduct its tests to present results during Q2 2025. This demonstrates the significant need for process water treatment in Sweden and the Nordic region, and this is just the beginning. We encourage more customers to reach out to us so that we can also assist them with their process water, says Isac Andersson, CEO of Xoma.

Smoltek's pioneering CNF-MIM technology paves the way for ultra-thin capacitors

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (publ) (“Smoltek” or “the Company”) has published a new interview in which Philip Lessner, CTO at Yageo Group, analyzes the latest developments in ultra-thin capacitors. In the interview, he explains why Smoltek's CNF-MIM technology can offer decisive advantages in the fast-growing semiconductor market.The market for ultra-thin capacitors is expected to grow strongly in the coming years, especially for advanced electronic applications such

Form 8.3 - Direct Line Insurance Group

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +----------------------------------------------+-------------------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+----------------------------------------------+-------------------------------+|(b) Owner or controller of interests and short|  ||positions disclosed, if different from

EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT. EQL Pharma AB (publ) (the “Company” or “EQL”) today announces that it has, through its wholly owned subsidiary EQL Pharma Int AB, signed a binding asset purchase agreement of DKK 120 million (corresponding to approximately SEK 185[1] million) (the “Asset Purchase Agreement”), to acquire a product portfolio. The product portfolio

Form 8.3 - Aviva Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +----------------------------------------+-------------------------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+----------------------------------------+-------------------------------------+|(b) Owner or controller of interests and|  ||short positions disclosed, if different

Form 8.3 - Britvic Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +------------------------------------------------+----------------------------+|(a) Full name of discloser: |Magnetar Capital Partners LP|+------------------------------------------------+----------------------------+|(b) Owner or controller of interests and short |  ||positions disclosed, if different from 1(a):

DanCann Pharma A/S: DanCann Pharma Announces Outcome of Directed Issues to Board and Management

COPENHAGEN, Denmark, 10 December 2024 – The Board of Directors of DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces the outcome of the directed issues of shares and warrants to Jeppe Krog Rasmussen, Carsten Trads, Jes Lunde and Christian Carlsen as decided by the Extraordinary General Meeting on 10 December 2024 (the ”Directed Issues”). All 200,000,000 shares and 100,000,000 warrants of series TO3 were subscribed for and allocated in accordance with the decision of the Extraordinary General Meeting.The Directed Issues

DanCann Pharma A/S: Minutes of Extraordinary General Meeting

[Pressemeddelelser | Dancann Pharma] held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”) on Tuesday, 10 December 2024 at 09:00 am (CET) On 10 December 2024 at 9:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the extraordinary general meeting was as follows: Proposed resolution to elect one (1) new additional member of the board 1. of directors (proposed by the board of directors)     Proposed resolution to issue shares to members of the executive

Result of AGM

Fidelity Emerging Markets Limited (the 'Company') Legal Entity Identifier: 213800HWWQPUJ4K1GS84   Result of Annual General Meeting   Following the Annual General Meeting ('AGM') of the Company, which was held earlier today, the Board is pleased to announce that all ordinary and special resolutions set out in the Notice of the Meeting were duly passed.   Resolution 5 proposed the payment of a final dividend of 20.0 US cents per Participating Preference Share in respect of the financial year ended 30 June 2024. As per the announcement made on 15 November 2024, the

Aptahem's Scientific Manuscript now Published in the British Journal of Pharmacology

Aptahem announced on 10 September 2024 that their scientific manuscript had been accepted for publication in the British Journal of Pharmacology (BJP). On the 9th December 2024, the article has been published.Read the article, titled “Antithrombotic but not anticoagulant activity of the thrombin-binding RNA aptamer Apta-1”, via this link . The article describes the results of the preclinical and mechanistic studies that have been performed by Aptahem and in a collaboration during several years with Örebro University. The study

Revised 2024 financial expectations and Accelerate25XL strategy update

Company Announcement no. 17/202410 December 2024 This announcement contains inside information concerning 2024 expectations and the Accelerate25XL strategy The Board of Directors for Wirtek A/S has today reviewed an updated financial prognosis for fiscal year 2024. Based on this review, the Board of Directors revises the 2024 financial expectations as follows: · Revenue for 2024 is expected in the range of DKK 72.5m – 73.5m, down from the previously announced DKK 74.0m – 78m. · EBITDA for 2024 is expected in the range of DKK 5.0m – 6.0m, down from previously announced DKK 6.

There are no items matching the current filter
There are no more items matching the current filter
Back to top